Aprea therapeutics, inc.APRE.US Overview

US StockHealthcare

(No presentation for APRE)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

APRE Overall Performance

APRE AI Analysis & Strategy

APRE Recent Performance

5.46%

Aprea therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

APRE PowerScanner

APRE Key Information

APRE Valuation Metrics

APRE Earnings Table

APRE Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.